The secondary endpoints include the amount and percent rate of change in eGFR from baseline to week 108 , the amount and percent rate of change in SUA concentration from baseline to week 108 , the proportion of patients who achieved an SUA concentration6 .0 mg/dL , and the incidence of renal function deterioration .